Master Clinical Pharmacologist
US FDA, Maryland, United States
Xiling Jiang, Ph.D. is a Master Clinical Pharmacology reviewer in the Division of Cancer Pharmacology I, Office of Clinical Pharmacology, at the US Food and Drug Administration, where she serves as a subject matter expert on clinical pharmacology issues for T cell redirecting bispecific antibody treatment.
Xiling received her B.S. degree in Medicinal Chemistry and M.S. degree in Pharmacology both from China Pharmaceutical University and received her Ph.D. degree in Pharmaceutical Sciences from University at Buffalo. She also finished post-doctoral trainings at University of Florida and US FDA, where her research included pediatric dosing and personalized medicine using quantitative approach. Prior to joining the US FDA, Xiling worked at Janssen Research & Development, LLC, where she supported translational and clinical pharmacology of biological products, with a major focus on mechanistic PK/PD modeling of immune-oncology agents.
Disclosure(s): No financial relationships to disclose
Wednesday, November 13, 2024
10:45 AM – 12:15 PM MST
Use of quantitative tools to facilitate TCE developmentâCRS and beyond
Wednesday, November 13, 2024
10:50 AM – 11:05 AM MST
